.Attributes Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA study, after a mean consequence of 11 months, individuals along with metastatic gastrointestinal growths that got biomarker-matched treatments based upon flowing lump DNA profiling revealed a better professional perk than those getting unrivaled treatment.